Code Bio is a company developing precision genetic medicines to treat life-threatening diseases. The company leverages its proprietary synthetic DNA delivery platform, 3DNA®, to overcome challenges in genetic medicine delivery.

Code Biotherapeutics

Code Bio

Code Bio was founded on the belief that more can be done for people living with debilitating genetic diseases. We are driven by the potential of our transformative technology to deliver precision genetic medicines for patients.

Code Bio leverages its proprietary, novel, multivalent, synthetic DNA delivery platform, 3DNA®, which has been engineered to overcome many of the challenges inherent with delivery of genetic medicines, such as: dose related toxicity, off-target effects, immunogenicity, gene size and delivery limitations, bioavailability, ability to re-dose, and vector manufacturing complexity.

The Company is advancing an internal pipeline focusing on a variety of diseases with its most advanced research in Duchenne’s Muscular Dystrophy (DMD). Code Bio also has research programs underway based on targeting data focused on the lungs, pancreas, and liver.

New Enterprise Associates

CureDuchenne Ventures

4BIO Capital

Takeda Ventures

UPMC Enterprises

JDRF T1D Fund

Northpond Ventures

Amgen Ventures

Hatteras Venture Partners

UCB Ventures

Looking forward to moderating a panel at the Longwood Healthcare Leaders conference next week discussing Pipeline Positioning with an exceptional group of biotech CEO panelists including Brendan Smith, CEO of Doppler Bio, Joanne Smith-Farrell, CEO of Be Bio, Lara S. Sullivan, M.D., CEO of Pyxis Oncology, and Ming Wang, CEO of Phanes Therapeutics.

Our Chief Scientific Officer, David Anderson, and Chief Business Officer, Lauren Kaskiel represented Code Bio at the European Society of Gene and Cell Therapy 30th Annual Congress! Check out these behind-the-scenes snapshots as they #network, learn, and collaborate with industry leaders. #ESGCT

We’re thrilled to be attending the J.P. Morgan Healthcare Conference in a few weeks! We are looking forward to sharing our progress in developing our novel non-viral 3DNA platform and pipeline that overcomes current #geneticmedicine delivery challenges. See you there! #JPM24

Our Chief Scientific Officer, David Anderson, is presenting for Code Bio at Chardan 's 7th Annual Genetic Medicines Conference. This conference highlights genetic medicines through featured fireside chats, presentations, panel discussions and spotlights perspectives from groundbreaking thought leaders: https://bit.ly/3LIc7zl

#CGMC2023 #ChardanGMConf

Our Chief Scientific Officer, David Anderson, Ph.D., will be presenting at the Oppenheimer & Co. Inc. 34th Annual #Healthcare Life Sciences Conference on February 14. We’re excited to connect with #investors to showcase the strides Code Bio is making as we advance a new class of precision #geneticmedicine. Learn more: https://bit.ly/3SnWwYc #OPCOLifeSciences

Our CEO, Brian McVeigh will be sharing his experience at the Goodwin & KPMG US 5th Annual Symposium during the J.P. Morgan Healthcare Conference. Learn more: https://bit.ly/3Rv4MXl #JPM24

CODE

COM:CODEBIOTX

Code Bio

name

homepage url

country

linkedin url

employee count

sector

industry

Description

peer of

investor of

Metrics